Skip to NavigationSkip to content

Pharmafile - Sales and Marketing News

AstraZeneca has jettisoned another non-essential asset with the sale of Synagis (palivizumab), a preventative treatment for infections relating to...
MSD’s blockbuster immunotherapy Keytruda has secured another FDA approval, this time for the treatment of hepatocellular carcinoma (HCC) in...
Food and Drug Administration (FDA) commissioner Scott Gottlieb has said that if a more rigorous approval process is introduced for opioids, the...
AstraZeneca has revealed new data for its sodium-glucose co-transporter 2 (SGLT2) inhibitor Farxiga (dapagliflozin) at the American Heart...
The UK government’s request that pharmaceutical companies stockpile an additional six weeks’ worth of medicine, in preparation for a no-deal Brexit...
Hundreds have died in a recent outbreak of Ebola in the Democratic Republic of Congo (DRC), in what has been described as the worst outbreak in the...
Eisai has revealed that its multireceptor Tyrosine Kinase Inhibitor Lenvima (lenvatinib) has been recommended by NICE, meaning it can now be used...
Check out this week’s top ten most popular stories on Pharmafile.com!
Britain’s cost effectiveness body the National Institute of Health and Care Excellence (NICE) has chosen not to recommend AstraZeneca’s Olaparib...
The NHS in England is now spending over £1billion a year on diabetes prescriptions, almost doubling in the last decade, according to NHS Digital.
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches